title: [Treatment of Guillain-Barré Syndrome].
abstract: The treatment of Guillain-Barre syndromé (GBS) was mainly symptomatic until the 1950s, followed by corticosteroid treatment in the 1950s through 1960s. Plasma exchange (PE) was then performed during 1970s through the 1980s, after which intravenous immunoglobulin (IVIg) was performed in 1990s through the 2000s. The effectiveness of IVIg and PE has been established by randomized controlled trial(RCT). Recently, new treatments using biological products have been explored. In this paper, we summarize the development of the treatment of GBS.
authors.affiliation: Department of Neurology, Saitama Medical Center.
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Nomura
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000818:Animals; D020275:Guillain-Barre Syndrome / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D010951:Plasma Exchange; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D016756:Immunoglobulins, Intravenous